Cresset Asset Management LLC Sells 34,198 Shares of Fresenius Medical Care AG (NYSE:FMS)

Cresset Asset Management LLC lowered its stake in Fresenius Medical Care AG (NYSE:FMS) by 62.6% during the 4th quarter, HoldingsChannel.com reports. The fund owned 20,400 shares of the company’s stock after selling 34,198 shares during the quarter. Cresset Asset Management LLC’s holdings in Fresenius Medical Care were worth $462,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the stock. Jane Street Group LLC bought a new stake in Fresenius Medical Care in the fourth quarter valued at $447,000. Northern Trust Corp boosted its holdings in Fresenius Medical Care by 45.9% in the fourth quarter. Northern Trust Corp now owns 362,190 shares of the company’s stock valued at $8,200,000 after acquiring an additional 113,953 shares in the last quarter. Syon Capital LLC bought a new stake in Fresenius Medical Care in the fourth quarter valued at $262,000. Dimensional Fund Advisors LP boosted its holdings in Fresenius Medical Care by 86.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 22,820 shares of the company’s stock valued at $517,000 after acquiring an additional 10,600 shares in the last quarter. Finally, First Trust Advisors LP bought a new stake in Fresenius Medical Care in the fourth quarter valued at $501,000. Institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care Stock Performance

Shares of FMS stock opened at $27.84 on Thursday. Fresenius Medical Care AG has a 12 month low of $17.93 and a 12 month high of $28.59. The stock has a market cap of $16.34 billion, a PE ratio of 23.01, a price-to-earnings-growth ratio of 0.76 and a beta of 0.85. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. The company’s fifty day moving average price is $24.80 and its 200-day moving average price is $23.56.

Fresenius Medical Care (NYSE:FMS) last announced its earnings results on Tuesday, May 6th. The company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.43 by $0.01. Fresenius Medical Care had a net margin of 3.43% and a return on equity of 6.04%. The firm had revenue of $5.54 billion for the quarter, compared to analysts’ expectations of $4.71 billion. On average, equities analysts expect that Fresenius Medical Care AG will post 1.51 EPS for the current fiscal year.

Fresenius Medical Care Increases Dividend

The business also recently declared an annual dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 23rd will be given a $0.7871 dividend. This represents a dividend yield of 1.9%. The ex-dividend date of this dividend is Friday, May 23rd. This is a positive change from Fresenius Medical Care’s previous annual dividend of $0.44. Fresenius Medical Care’s payout ratio is currently 49.11%.

Analyst Ratings Changes

Several research firms recently weighed in on FMS. Truist Financial lifted their price target on shares of Fresenius Medical Care from $25.00 to $30.00 and gave the company a “hold” rating in a report on Monday. StockNews.com upgraded shares of Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.